Home - Newsroom - Contact  
Ferring Pharmaceuticals About Ferring Fertility Products Orthopaedic Products Urology Products Other Products Ferring Fertility Euflexxa Euflexxa

Ferring Pharmaceuticals Inc. (US division) is a research-based biopharmaceutical company that offers treatments for patients with infertility, osteoarthritis of the knee, and lower urinary tract disorders. Our parent company, The Ferring Group, was founded in 1950 as a research-driven specialty pharmaceutical company. With worldwide annual sales of approximately $1 billion, this global company focuses on 6 therapeutic areas: urology, infertility, obstetrics, gastroenterology, endocrinology, and osteoarthritis.

The US division of Ferring is the leading provider of gonadotropins for infertility treatment. Products include the foundation of mixed protocol, MENOPUR® (menotropins for injection, USP), and its perfect partner, BRAVELLE® (urofollitropin for injection, purified). Also, Ferring introduced EUFLEXXA™, the first bioengineered injectable hyaluronic acid approved in the US for the treatment of osteoarthritis of the knee. Over the past 10 years, Ferring has been developing a pipeline of urology products, several of which are currently in Phase II or III trials. Ferring also recently acquired and relaunched Prosed® DS, a prescription tablet for the treatment of urinary tract pain and discomfort.




    In The News:

  • Win A $10,000 Education Fund For Your Miracle Child
  • FDA Approves Ferring Pharmaceuticals� Endometrin® For Luteal Phase Support In Assisted Reproductive Technology Treatment
  • Ferring Reports On Endometrin® Presentations At Pacific Coast Reproductive Society Annual Meeting
  • Ferring Pharmaceuticals Announces 2007 My Little Miracle Essay Contest
  • Comparative Study Shows Safer, More Controlled Stimulation With MENOPUR® Than GONAL-f® In Ovulation Induction
  • Nationwide Survey Finds Only 30 Percent Of Patients Undrgoing Infertility Treatment Are Able To Administer Their Medications With One Injection Per Day
  • Ferring Pharmaceuticals Announces Euflexxa™ Labeling Extended To Include Room Temperature Storage
  • Ferring Pharmaceuticals Announces 2006 My Little Miracle Essay Contest
  • Ferring Pharmaceuticals Announces Bruce Jenner As National Spokesperson For Euflexxa™
  • Head-To-Head Study Shows Euflexxa™ Has Greater Tolerability Compared To Synvisc® For Osteoarthritis Knee Pain
  • Ferring Pharmaceuticals Announces Launch Of Euflexxa™ For
    Osteoarthritis Knee Pain

  • Ferring Pharmaceuticals Obtains Rights To EUFLEXXA�
  • Ferring Pharmaceuticals Announces 2005 My Little Miracle Essay Contest
  • Ferring Pharmaceuticals Appoints William Garbarini As Senior Director Of Marketing
  • Ferring Pharmaceuticals Appoints Olivier Delannoy As Vice President, Infertility Business Unit
  • Ferring Pharmaceuticals Announces Launch Of New Treatment For Infertility
  • Michael Seckler Appointed National Sales Director For Ferring Pharmaceuticals
  • Oak Brook Fertility Celebrates With Its Patient Named As Winner Of Ferring's My Little Miracle Essay Contest
  • Georgia Reproductive Specialists Celebrates With Its Patient Named As Winner Of Ferring's My Little Miracle Essay Contest
  • Family Beginnings Celebrates With Its Patients Named As Winners Of Ferring's My Little Miracle Essay Contest
  • Local Fertility Practice Celebrates Patient Named As Winner Of Ferring's My Little Miracle Essay Contest
  • Local Woman Wins $1,000 For Her 19-Month-Old Son
  • Local Man Wins $5,000 For His 11-Month-Old Children
  • Ferring Supports Symposium On Optimizing Assisted Reproductive Technology (ART)
  • Ferring Presents $10,000 Grand Prize To Winner Of My Little Miracle Essay Contest
  • Society For Reproductive Endocrinology And Infertility Announces Ferring Pharmaceuticals' Sponsorship Of Fellows' Retreat 2005-2007
  • Ferring Introduces Bravelle® With First NEEDLE-FREE Reconstitution Device

View all Press Releases




Baby Contest

1. Source: NDCHealth, June 2001.
©2002 Ferring Pharmaceuticals
Non-US visitors, please go to our international site at www.ferring.com
 

Legal Notice
�